Abstract
Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Carboplatin / administration & dosage
-
Carboplatin / adverse effects
-
Female
-
Follow-Up Studies
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
Humans
-
Leukopenia / chemically induced
-
Neoplasm Metastasis
-
Phlebitis / chemically induced
-
Remission Induction
-
Salvage Therapy
-
Treatment Outcome
-
Vinblastine / administration & dosage
-
Vinblastine / adverse effects
-
Vinblastine / analogs & derivatives
-
Vinorelbine
Substances
-
Granulocyte Colony-Stimulating Factor
-
Vinblastine
-
Carboplatin
-
Vinorelbine